共 157 条
[21]
Benussi S(2015)Dabigatran concentration: variability and potential bleeding prediction in ‘real-life’ patients with atrial fibrillation Basic Clin Pharmacol Toxicol 75 1069-47
[22]
Kotecha D(2019)Intra- and inter- individual rivaroxaban concentrations and potential bleeding risk in patients with atrial fibrillation Eur J Clin Pharmacol 132 749-164
[23]
Ahlsson A(2019)Net clinical benefit of non-vitamin K antagonist versus vitamin K antagonist anticoagulants in elderly patients with atrial fibrillation Am J Med 281 56-183
[24]
Atar D(2019)Patients aged 90 years or older with atrial fibrillation treated with oral anticoagulants: a multicentre observational study Int J Cardiol 138 37-900
[25]
Casadei B(2018)Oral anticoagulation in very elderly patients with atrial fibrillation: a nationwide cohort study Circulation 131 157-undefined
[26]
Camm AJ(2015)Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation Circulation 175 175-undefined
[27]
Accetta G(2016)History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the apixaban for reduction in stroke and Other thromboembolic events in atrial fibrillation trial Am Heart J 63 891-undefined
[28]
Ambrosio G(2014)Factors associated with major bleeding events J Am Coll Cardiol undefined undefined-undefined
[29]
Atar D(undefined)undefined undefined undefined undefined-undefined
[30]
Bassand J-P(undefined)undefined undefined undefined undefined-undefined